Monday, March 12, 2012

Benefit-Risk Balance Deemed Positive for Type 2 Diabetics Taking Pioglitazone

Following safety reviews of the drug pioglitazone—a medicine used in the treatment of Type 2 diabetes—the European Medicines Agency delivered their decision that while there is a marginally increased risk of bladder cancer in those taking the drug, it remains a viable treatment option for some patients. Pioglitazone, also sold under the brand name Actos, is used along with a sensible diet and exercise program to increase the body’s sensitivity to insulin, thereby controlling blood sugar levels.

Reducing Potential Risks
The EMA’s conclusions following extensive study of the drug was that the slight increased risk of bladder cancer could be alleviated through implementation of a more stringent screening of potential patients. Medical professionals are warned against prescribing pioglitazone in any patients with a history of bladder cancer, and to exercise caution when prescribing the drug to the elderly as well. Those patients deemed good candidates for pioglitazone should nonetheless be monitored closely every three to six months to ensure the benefits continue to outweigh the risks.

High Doses, Significant Duration Linked
The results of the controlled epidemiological studies determined that the small risk associated with pioglitazone was seen primarily in those patients who took the drug for significant lengths of time and in the highest doses. Even though the studies showed only a 0.15% increase in risk of bladder cancer this does not mean that those who are prescribed the drug for short term use have no risk at all of contracting bladder cancer.

Further Studies Necessary
Following a series of studies on the drug, the EMA’s Committee for Medicinal Products for Human Use (CHMP) believes there is further need for analysis of the types and severity of bladder cancer in those patients treated with the drug. The CHMP hopes to reveal any possible correlation between incidence of bladder cancer and the age of the patient, the dose of the drug or the duration of the use in further studies. In short, medical professionals are advised to continue to use pioglitazone in those patients who are responding positively to the drug, operating under the belief that the advantages outweigh the possible risks.

Notice to Current Users of Pioglitazone
It is extremely important that patients who currently take pioglitazone follow the directions given by their physician exactly, never taking more or less than directed, and discussing any concerns with a medical professional. While pioglitazone controls Type 2 diabetes, it cannot cure it, and can take as long as two weeks to begin stabilizing your blood sugar. Many patients are started on the lowest dosage which is then gradually increased until full health benefits are reached. The goal of further study is to more fully characterize the associated risks of the drug as well as determine specific measures for minimizing those risks.

Author: Sullo & Sullo Attorneys

0 Comments

Categories: ImportedNumber of views: 1948

Tags: actos dangers actos recall actos Warnings

Please login or register to post comments.

250,000 CLIENTS REPRESENTED

FREE CASE REVIEW

Full Name* Email* Telephone Number* Are You already a Client?* Type of Case* Tell Us About Your Case*

WARNING: Do not send any information in any email through this website if you consider the information confidential or privileged.

I understand that by submitting my contact information to Sullo & Sullo LLP for review, I consent to messages regarding this legal matter as well as marketing for other potential legal matters in the future without limitation at standard messaging and data rates unless terminated by me in writing. I further understand that my submission of any and all information in response to this website does NOT create a lawyer-client relationship between myself and Sullo & Sullo, LLP and/or its lawyers, and that any and all information submitted is NOT confidential or privileged. I further acknowledge that, unless Sullo & Sullo, LLP subsequently enters into an Attorney-Client relationship with me, any and all information I provide will NOT be treated as confidential or privileged, and any such information may be used against me and/or for the benefit of current or future clients of Sullo & Sullo, LLP. ...READ ENTIRE DISCLAIMER

Receive an Immediate Response

ANDREW SULLO IS A TOP 100 NATIONAL TRIAL LAWYER 2013 • 2014 • 2015 • 2016 • 2017 • 2018 • 2019

Obtener una Respuesta Inmediata

Andrew Sullo – 100 Mejores Abogados Nacional | 2013 • 2014 • 2015 • 2016 • 2017